News from ODYSSEY OUTCOMES: Effects of PCSK9 inhibition on total cardiovascular disease burden New US Cholesterol Guidelines: The good, the bad and the ugly New US FDA approval for alirocumab Familial hypercholesterolaemia in China – registry urgently needed OSLER 5-year data in Japanese: evolocumab continues to impress Who is receiving PCSK9 inhibitors in the real world?ODYSSEY OUTCOMES Economics Study: How can we get the best value from PCSK9 inhibitors?Alirocumab safe in patients with diabetes mellitus

Latest News Updates

Home Education & Resources

Education & Resources

Slides

Inclisiran and the ORION clinical development programme

Inclisiran and the ORION clinical development programme

Evolution of PCSK9 inhibitors: Pipedream or Evidence based Reality

Evolution of PCSK9 inhibitors: Pipedream or Evidence based Reality

How do we recognize FH in clinical practice?

How do we recognize FH in clinical practice?

PCSK9 Inhibitors: A View of Clinical Studies

PCSK9 Inhibitors: A View of Clinical Studies

FH in children and adolescents

FH in children and adolescents View all slides »

Videos

Play

BANTING study in type 2 diabetes: evolocumab improves lipid goals and postprandial lipids

BANTING study in type 2 diabetes: evolocumab improves lipid goals and postprandial lipids

Play

AHA/ACC 2018 Cholesterol Guidelines also have good points

AHA/ACC 2018 Cholesterol Guidelines also have good points

Play

Coronary artery calcium for stratifying risk in familial hypercholesterolaemia

Coronary artery calcium for stratifying risk in familial hypercholesterolaemia

Play

PCSK9 Forum Inhibitors and Health Economics

PCSK9 Forum Inhibitors and Health Economics

View all videos »

Events

Cardiometabolic Health Congress 2019 (CMHC 2019)
Event start date: 3 May 2019
Pheonix, USA

Asian Pacific Society of Cardiology Congress 2019 (APSC 2019)
Event start date: 22 May 2019
Manila, The Philippines

87th European Atherosclerosis Society
Event start date: 26 May 2019
Maastricht, The Netherlands

View all events »

Trials

View all trials »

Links

View all links »

Guidelines & Consensus Guidance

View all guidelines »

Archived articles

View the archive »

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. The PCSK9 Education and Research Forum is focused on raising awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target. As part of its remit, PCSK9 Education and Research Forum offers healthcare professionals open access to electronic and multimedia platforms providing real-time reporting of significant developments and news; authoritative analysis and commentary; as well as an extensive library of accredited educational materials tailored to the differing needs of registrants.

Our Partnership and Outreach

Through its unique global network of researchers and clinicians, the PCSK9 Education and Research Forum connects academic institutions, research organisations and societies which share the Forum’s commitment to the reduction of CVD mortality and morbidity through improved management of atherosclerotic dyslipidaemia. The Forum builds on educational partnerships with such organisations through jointly sponsored symposia, as well as accredited research and educational programmes.

Educational Partners and Supporters

Amgen

The Medicines Company

Sanofi Regeneron

Amgen

The Medicines Company

Sanofi Regeneron

Amgen

The Medicines Company

Sanofi Regeneron

The Medicines Company

Sanofi Regeneron

© Copyright 2019 PCSK9 Forum. All rights reserved